Journal: Molecular Vision

Article Title: Immunohistochemical changes in rat retinas at various time periods of elevated intraocular pressure

doi:

Figure Lengend Snippet: List of primary antibodies used in this study

Article Snippet: Brain Derived Neurotrophic Factor (BDNF) , Rabbit polyclonal , Santa Cruz, SC-546 , 1:500 , Amacrine cells and subpopulations of RGCs.

Techniques: Concentration Assay, Derivative Assay

Journal: Molecular Vision

Article Title: Immunohistochemical changes in rat retinas at various time periods of elevated intraocular pressure

doi:

Figure Lengend Snippet: Fluorescent immunoreactivity of BDNF in control and glaucomatous retinas. Control retinas ( A and B ), and experimental glaucomatous retinas after one week ( C ) and five weeks ( D ) of elevated IOP. Abbreviations: brain derived neurotrophic factor (BDNF), ganglion cell layer (GCL), inner nuclear layer (INL), intraocular pressure (IOP), inner plexiform layer (IPL), outer nuclear layer (ONL), outer plexiform layer (OPL). Scale bar equals 20 μm.

Article Snippet: Brain Derived Neurotrophic Factor (BDNF) , Rabbit polyclonal , Santa Cruz, SC-546 , 1:500 , Amacrine cells and subpopulations of RGCs.

Techniques: Derivative Assay

Journal: Theranostics

Article Title: Upregulation of neuronal PGC-1α ameliorates cognitive impairment induced by chronic cerebral hypoperfusion

doi: 10.7150/thno.37119

Figure Lengend Snippet: PGC-1α induces hippocampal BDNF expression after chronic cerebral hypoperfusion. Representative images of brain sections immunostained for BDNF ( A, B ), and Western blots for BDNF ( C ) showed that BDNF protein was significantly downregulated in WT+BCAS and PGC-1α f/f +BCAS groups compared to the sham group. By contrast, BDNF was up-regulated in the nPGC-1α+BCAS group. ( D, E ) Immunostaining in hippocampal CA1 area showed that there was only a downward trend for the numbers of NeuN-positive neurons in the WT+BCAS and PGC-1α f/f +BCAS groups compared to the sham and nPGC-1α+BCAS groups. *p<0.05 as determined by one-way ANOVA. n = 5 in each group.

Article Snippet: After perforating with 0.2% Triton X-100 for 15 min, brain sections were blocked with 3% bovine serum albumin (BSA) for 30 min. Next, sections were incubated with the primary antibodies, including rabbit anti-brain-derived neurotrophic factor (BDNF) (1:500; Santa Cruz) and rabbit anti-neuron-specific DNA-binding protein (NeuN) (1:500; Abcam), overnight at 4°C.

Techniques: Expressing, Western Blot, Immunostaining

Journal: Neuropsychiatric Disease and Treatment

Article Title: Rapamycin modulated brain-derived neurotrophic factor and B-cell lymphoma 2 to mitigate autism spectrum disorder in rats

doi: 10.2147/NDT.S125088

Figure Lengend Snippet: The expression of Bcl-2 and BDNF was examined by immunohistochemistry. Notes: Signals of Bcl-2 ( A ) and BDNF ( B ) in hippocampus from different groups were analyzed by immunohistochemistry. Five high-powered fields were randomly chosen for analysis under 200× magnification using an inverted microscope. The positive cells were stained in brown or dark nankeen (marked with arrows). RAPA group, the offspring of control rats were administered with rapamycin; ASD + RAPA group, the offspring of VPA rats were injected with rapamycin. The positive rate was quantified with ImageJ software by counting the average optical density. Abbreviations: Bcl-2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; VPA, valproic acid; RAPA, rapamycin; ASD, autism spectrum disorder.

Article Snippet: Rabbit monoclonal anti-brain-derived neurotrophic factor (anti-BDNF), B-cell lymphoma 2 (Bcl-2), and mouse monoclonal anti-GAPDH antibodies were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).

Techniques: Expressing, Immunohistochemistry, Inverted Microscopy, Staining, Injection, Software, Derivative Assay

Journal: Neuropsychiatric Disease and Treatment

Article Title: Rapamycin modulated brain-derived neurotrophic factor and B-cell lymphoma 2 to mitigate autism spectrum disorder in rats

doi: 10.2147/NDT.S125088

Figure Lengend Snippet: The protein levels of Bcl-2 and BDNF from different groups were detected by western blot. Notes: ( A ) Rapamycin released the levels of Bcl-2 and BDNF suppressed by VPA exposure. Proteins of hippocampus were extracted for western blot. ( B ) Bands were quantified by using Quantity One software. RAPA group, the offspring of control rats were administered with rapamycin; ASD + RAPA group, the offspring of VPA rats were injected with rapamycin. Compared with normal group, ** P <0.01; compared with ASD group, ## P <0.01. Abbreviations: Bcl-2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; VPA, valproic acid; RAPA, rapamycin; ASD, autism spectrum disorder.

Article Snippet: Rabbit monoclonal anti-brain-derived neurotrophic factor (anti-BDNF), B-cell lymphoma 2 (Bcl-2), and mouse monoclonal anti-GAPDH antibodies were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).

Techniques: Western Blot, Software, Injection, Derivative Assay

Journal: Mediators of Inflammation

Article Title: Sevoflurane Exacerbates Cognitive Impairment Induced by A β 1–40 in Rats through Initiating Neurotoxicity, Neuroinflammation, and Neuronal Apoptosis in Rat Hippocampus

doi: 10.1155/2018/3802324

Figure Lengend Snippet: Sevoflurane inhalation influenced protein expression of Bcl-xL, caspase-9, BDNF, RAGE, and mRNA level of IL-1 β , NF- κ B, and iNOS in the hippocampus. Caspase-9 (a, b), Bcl-xL (a, c), BDNF (d, e), and RAGE (d, f) protein levels in the NS- or A β -treated hippocampus of rats were determined using Western blot after inhaling 30% O 2 and 2.5% sevoflurane at the indicated times. Relative band intensity of each protein expression was calculated as % of the intensity of the β -actin protein band and expressed as a fold change in reference to their controls. IL-1 β (g), NF- κ B (h), and iNOS (i) mRNA levels in the NS- and A β -treated hippocampus were determined after inhaling 30% O 2 or 2.5% sevoflurane on day 7. The results were expressed as a fold change in reference to mRNA levels of their own controls. ∗ P < 0.05 vs. A β + O 2 ( n = 8); ∗∗ P < 0.01 vs. A β + O 2 ( n = 8).

Article Snippet: The membrane was individually incubated with anti-GPAP (dilution, 1 : 500), anti-IBA1 (dilution, 1 : 5 00), anti-Bcl-xL (dilution, 1 : 1000), anti-caspase-9 (dilution, 1 : 2000), anti-receptor for advanced glycation end products (RAGE) (dilution, 1 : 1000) or anti-brain-derived neurotrophic factor (BDNF) (dilution, 1 : 1000) (Santa Cruz, CA), and β -actin (dilution, 1 : 500) (BioVision, US) as the primary antibodies at 4°C overnight and then incubated with horseradish peroxidase-conjugated secondary antibody (dilution, 1 : 2000) after washing with TBS.

Techniques: Expressing, Western Blot

Journal: PLoS ONE

Article Title: Exercise Promotes Axon Regeneration of Newborn Striatonigral and Corticonigral Projection Neurons in Rats after Ischemic Stroke

doi: 10.1371/journal.pone.0080139

Figure Lengend Snippet: Brain protein samples from rats subjected to MCAO for 30: Western blot results and corresponding densitometric analysis showed that the levels of BDNF, SYN and VEGF were increased in MCAO+Ex group compared with MCAO group; and that Nogo-A levels were reduced in the MCAO+Ex group. C: Correlation results showed that SYN levels were increased after exercise and were negatively correlated with Nogo-A levels in ischemic rat brain. Data are shown as mean ± S.E.M. * P <0.05 vs MCAO group; MCAO group (n = 4); MCAO+Ex group (n = 5).

Article Snippet: The membranes were then blocked with 10% non-fat milk in Tris-HCl (10 mM, pH 7.4) containing 150 mM NaCl, and 1% Nonidet P-40, and separately incubated with the following specific antibodies at 4°C overnight: rabbit polyclonal anti-brain-derived neurotrophic factor (BDNF, Santa Cruz Biotechnology, Santa Cruz, CA, USA,1∶500 dilution), rabbit polyclonal anti-synapsin (SYN, Sigma, USA, 1∶1000), rabbit monoclonal anti-growth associated protein 43 (GAP43, Chemicon, Temecula, CA, USA, 1∶1000), mouse polyclonal anti-neurite growth inhibitor-A (Nogo-A, BD Transduction Laboratories, 1∶1000), rabbit polyclonal anti-vascular endothelial growth factor (VEGF, Santa Cruz 1∶500), goat polyclonal anti-glial fibrillary acidic protein (GFAP, Abcam, Cambridge, UK, 1∶2000), mouse monoclonal anti-tyrosine hydroxylase (TH, Sigma, 1∶1000), or mouse monoclonal anti-actin (Sigma, 1∶1000).

Techniques: Western Blot

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Neuroprotective Effect and Molecular Mechanism of [6]-Gingerol against Scopolamine-Induced Amnesia in C57BL/6 Mice

doi: 10.1155/2018/8941564

Figure Lengend Snippet: Effect of GIN on the SCO-reduced protein expression of BDNF in the cortex. Mice were pretreated with GIN for 3 days before the start of the test and then continuously administered during the behavior tests. The protein expression ratios of BDNF/actin (a) and p-Akt/Akt (c) were monitored via western blot analysis. Data were presented as mean ± SEM ( n = 3). Significant difference between the groups: ∗ p < 0.05, vehicle-treated control versus SCO group; # p < 0.05, SCO alone group versus GIN-treated group in combination with SCO. (b) Effect of GIN on the activation of CREB via phosphorylation in the cortex was examined via immunohistochemistry by staining with anti-p-CREB antibody (right panel). (A) sham control, (B) SCO (1 mg/kg), (C) SCO (1 mg/kg) + GIN (10 mg/kg), (D) SCO (1 mg/kg) + GIN (25 mg/kg). The protein levels of p-CREB and CREB were also verified by western blot analysis (left panel).

Article Snippet: Anti-Akt and anti-brain-derived neurotrophic factor (BDNF) antibodies were provided by Santa Cruz Biotechnology (CA, USA), and anti-actin antibody and other chemical reagents were bought from Sigma-Aldrich.

Techniques: Expressing, Western Blot, Activation Assay, Immunohistochemistry, Staining